New drug duo shows promise against aggressive colon cancer
NCT ID NCT05890742
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving two immunotherapy drugs (IBI310 and sintilimab) before surgery can eliminate or shrink tumors in people with a specific genetic type of colon cancer (MSI-H/dMMR). About 453 adults with stage IIB or III colon cancer that can be surgically removed will receive the drug combination before their operation. The main goals are to see if the cancer completely disappears after treatment and to measure how long patients remain cancer-free.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR-DEFICIENT RESECTABLE COLON CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.